Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (14017)	7/8/2000 6:50:22 AM
From: Robert K.	Respond to of 17367

And bluegreens point is that bax and allergan HAVE seen the data , while we have not. Of course the converse argument is the fda HAS seen the data and wants more. Cacaito, if zovant had 396 data entrants and most of the trial canditates died before trial entry, then do you think the dsmb would have given zovant the nod? Conversely if xoma had 1500plus meningo entrants and or was able to treat earlier in the course, then do you think that would suffice the more data requirement from fda?......... So is it the drug or is it the trials? Science supports bpi. You can continue you proclaimation that bpi does not work. But...Bax calls the shots on bpi now....we will see.... Standard K